Zobrazeno 1 - 10
of 60
pro vyhledávání: '"R. Mohanlal"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
South African Medical Journal, Vol 107, Iss 10, Pp S7-S11 (2017)
Background. Without timely surgical intervention, most children with biliary atresia (BA) are not expected to live beyond 2 years of age. The initial intervention, the Kasai hepatoportoenterostomy (KPE), aims to achieve biliary drainage. Liver transp
Externí odkaz:
https://doaj.org/article/6fc1f775530b47dfb2edf7c2731797d9
Publikováno v:
Annals of Oncology. 33:S1541
Publikováno v:
Annals of Oncology. 33:S1271
Publikováno v:
Annals of Oncology
Background: Due to COVID-19, the NCCN Myeloid Growth Factor Panel expanded prophylactic G-CSF use to chemotherapy with Intermediate Risk (10%-20% risk) of Febrile Neutropenia (FN), and to Low Risk FN patients (pts) who previously developed FN Preserv
Autor:
L. Huang, L. Du, Yuankai Shi, Goetz H. Kloecker, Y. Sun, R. Mohanlal, T. Feinstein, Baohui Han, Lyudmilla Bazhenova
Publikováno v:
Journal of Thoracic Oncology. 14:S647-S648
Publikováno v:
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 107(10)
Without timely surgical intervention, most children with biliary atresia (BA) are not expected to live beyond 2 years of age. The initial intervention, the Kasai hepatoportoenterostomy (KPE), aims to achieve biliary drainage. Liver transplantation (L
Autor:
L. Huang, R. Mohanlal
Publikováno v:
Annals of Oncology. 30:v660
Background The PD-L1 inhibitors Avelumab (AV) and Atezolizumab (AT) have proven clinical anticancer efficacy, however in NSCLC trials, Javelin Lung 200 (JAV for AV) failed, whereas OAK (for AT) met primary endpoint showing better survival vs 75 mg/m2
Publikováno v:
Journal of Thoracic Oncology. 14:S359
Publikováno v:
Value in Health. 22:S109